Although previous studies have investigated and compared the differences in clinical characteristics and prognosis between HER2‐low and HER2‐zero BC, the larger sample size and relatively longer follow‐up time corroborated this study with more credible results than previous studies. This evidence concerns the gene ERBB2 and breast cancer.